

# Myelodysplastic Syndrome-Global Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/M089E7D000AMEN.html>

Date: May 2018

Pages: 158

Price: US\$ 2,480.00 (Single User License)

ID: M089E7D000AMEN

## Abstracts

### Report Summary

Myelodysplastic Syndrome-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Myelodysplastic Syndrome industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Myelodysplastic Syndrome 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Myelodysplastic Syndrome worldwide, with company and product introduction, position in the Myelodysplastic Syndrome market  
Market status and development trend of Myelodysplastic Syndrome by types and applications

Cost and profit status of Myelodysplastic Syndrome, and marketing status

Market growth drivers and challenges

The report segments the global Myelodysplastic Syndrome market as:

Global Myelodysplastic Syndrome Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Myelodysplastic Syndrome Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alkylating Agents

Cytotoxic Antibiotics

Topoisomerase Inhibitors

Others

Global Myelodysplastic Syndrome Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinic

Global Myelodysplastic Syndrome Market: Manufacturers Segment Analysis (Company and Product introduction, Myelodysplastic Syndrome Sales Volume, Revenue, Price and Gross Margin):

Celgene

Novartis

Otsuka

Actinium Pharmaceuticals

Accelaron Pharma

Bellicum Pharmaceuticals

Cornerstone Pharmaceuticals

CTI BioPharma

Onconova Therapeutics

Strategia Therapeutics

KaloBios Pharmaceuticals

Kiadis Pharma

Mirati Therapeutics

Astex

Celator Pharmaceuticals

Eli-lilly

Sunesis Pharmaceuticals

Targazyme

Gamida Cell  
GlaxoSmithKline  
Sumitomo Dainippon Pharma  
TetraLogic Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF MYELODYSPLASTIC SYNDROME**

- 1.1 Definition of Myelodysplastic Syndrome in This Report
- 1.2 Commercial Types of Myelodysplastic Syndrome
  - 1.2.1 Alkylating Agents
  - 1.2.2 Cytotoxic Antibiotics
  - 1.2.3 Topoisomerase Inhibitors
  - 1.2.4 Others
- 1.3 Downstream Application of Myelodysplastic Syndrome
  - 1.3.1 Hospital
  - 1.3.2 Clinic
- 1.4 Development History of Myelodysplastic Syndrome
- 1.5 Market Status and Trend of Myelodysplastic Syndrome 2013-2023
  - 1.5.1 Global Myelodysplastic Syndrome Market Status and Trend 2013-2023
  - 1.5.2 Regional Myelodysplastic Syndrome Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Myelodysplastic Syndrome 2013-2017
- 2.2 Sales Market of Myelodysplastic Syndrome by Regions
  - 2.2.1 Sales Volume of Myelodysplastic Syndrome by Regions
  - 2.2.2 Sales Value of Myelodysplastic Syndrome by Regions
- 2.3 Production Market of Myelodysplastic Syndrome by Regions
- 2.4 Global Market Forecast of Myelodysplastic Syndrome 2018-2023
  - 2.4.1 Global Market Forecast of Myelodysplastic Syndrome 2018-2023
  - 2.4.2 Market Forecast of Myelodysplastic Syndrome by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Myelodysplastic Syndrome by Types
- 3.2 Sales Value of Myelodysplastic Syndrome by Types
- 3.3 Market Forecast of Myelodysplastic Syndrome by Types

### **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Global Sales Volume of Myelodysplastic Syndrome by Downstream Industry

## 4.2 Global Market Forecast of Myelodysplastic Syndrome by Downstream Industry

### **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

#### 5.1 North America Myelodysplastic Syndrome Market Status by Countries

5.1.1 North America Myelodysplastic Syndrome Sales by Countries (2013-2017)

5.1.2 North America Myelodysplastic Syndrome Revenue by Countries (2013-2017)

5.1.3 United States Myelodysplastic Syndrome Market Status (2013-2017)

5.1.4 Canada Myelodysplastic Syndrome Market Status (2013-2017)

5.1.5 Mexico Myelodysplastic Syndrome Market Status (2013-2017)

#### 5.2 North America Myelodysplastic Syndrome Market Status by Manufacturers

#### 5.3 North America Myelodysplastic Syndrome Market Status by Type (2013-2017)

5.3.1 North America Myelodysplastic Syndrome Sales by Type (2013-2017)

5.3.2 North America Myelodysplastic Syndrome Revenue by Type (2013-2017)

#### 5.4 North America Myelodysplastic Syndrome Market Status by Downstream Industry (2013-2017)

### **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

#### 6.1 Europe Myelodysplastic Syndrome Market Status by Countries

6.1.1 Europe Myelodysplastic Syndrome Sales by Countries (2013-2017)

6.1.2 Europe Myelodysplastic Syndrome Revenue by Countries (2013-2017)

6.1.3 Germany Myelodysplastic Syndrome Market Status (2013-2017)

6.1.4 UK Myelodysplastic Syndrome Market Status (2013-2017)

6.1.5 France Myelodysplastic Syndrome Market Status (2013-2017)

6.1.6 Italy Myelodysplastic Syndrome Market Status (2013-2017)

6.1.7 Russia Myelodysplastic Syndrome Market Status (2013-2017)

6.1.8 Spain Myelodysplastic Syndrome Market Status (2013-2017)

6.1.9 Benelux Myelodysplastic Syndrome Market Status (2013-2017)

#### 6.2 Europe Myelodysplastic Syndrome Market Status by Manufacturers

#### 6.3 Europe Myelodysplastic Syndrome Market Status by Type (2013-2017)

6.3.1 Europe Myelodysplastic Syndrome Sales by Type (2013-2017)

6.3.2 Europe Myelodysplastic Syndrome Revenue by Type (2013-2017)

#### 6.4 Europe Myelodysplastic Syndrome Market Status by Downstream Industry (2013-2017)

### **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE,**

## **MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 7.1 Asia Pacific Myelodysplastic Syndrome Market Status by Countries
  - 7.1.1 Asia Pacific Myelodysplastic Syndrome Sales by Countries (2013-2017)
  - 7.1.2 Asia Pacific Myelodysplastic Syndrome Revenue by Countries (2013-2017)
  - 7.1.3 China Myelodysplastic Syndrome Market Status (2013-2017)
  - 7.1.4 Japan Myelodysplastic Syndrome Market Status (2013-2017)
  - 7.1.5 India Myelodysplastic Syndrome Market Status (2013-2017)
  - 7.1.6 Southeast Asia Myelodysplastic Syndrome Market Status (2013-2017)
  - 7.1.7 Australia Myelodysplastic Syndrome Market Status (2013-2017)
- 7.2 Asia Pacific Myelodysplastic Syndrome Market Status by Manufacturers
- 7.3 Asia Pacific Myelodysplastic Syndrome Market Status by Type (2013-2017)
  - 7.3.1 Asia Pacific Myelodysplastic Syndrome Sales by Type (2013-2017)
  - 7.3.2 Asia Pacific Myelodysplastic Syndrome Revenue by Type (2013-2017)
- 7.4 Asia Pacific Myelodysplastic Syndrome Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 8.1 Latin America Myelodysplastic Syndrome Market Status by Countries
  - 8.1.1 Latin America Myelodysplastic Syndrome Sales by Countries (2013-2017)
  - 8.1.2 Latin America Myelodysplastic Syndrome Revenue by Countries (2013-2017)
  - 8.1.3 Brazil Myelodysplastic Syndrome Market Status (2013-2017)
  - 8.1.4 Argentina Myelodysplastic Syndrome Market Status (2013-2017)
  - 8.1.5 Colombia Myelodysplastic Syndrome Market Status (2013-2017)
- 8.2 Latin America Myelodysplastic Syndrome Market Status by Manufacturers
- 8.3 Latin America Myelodysplastic Syndrome Market Status by Type (2013-2017)
  - 8.3.1 Latin America Myelodysplastic Syndrome Sales by Type (2013-2017)
  - 8.3.2 Latin America Myelodysplastic Syndrome Revenue by Type (2013-2017)
- 8.4 Latin America Myelodysplastic Syndrome Market Status by Downstream Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 9.1 Middle East and Africa Myelodysplastic Syndrome Market Status by Countries
  - 9.1.1 Middle East and Africa Myelodysplastic Syndrome Sales by Countries (2013-2017)

9.1.2 Middle East and Africa Myelodysplastic Syndrome Revenue by Countries (2013-2017)

9.1.3 Middle East Myelodysplastic Syndrome Market Status (2013-2017)

9.1.4 Africa Myelodysplastic Syndrome Market Status (2013-2017)

9.2 Middle East and Africa Myelodysplastic Syndrome Market Status by Manufacturers

9.3 Middle East and Africa Myelodysplastic Syndrome Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Myelodysplastic Syndrome Sales by Type (2013-2017)

9.3.2 Middle East and Africa Myelodysplastic Syndrome Revenue by Type (2013-2017)

9.4 Middle East and Africa Myelodysplastic Syndrome Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF MYELOYDYSPLASTIC SYNDROME**

10.1 Global Economy Situation and Trend Overview

10.2 Myelodysplastic Syndrome Downstream Industry Situation and Trend Overview

## **CHAPTER 11 MYELOYDYSPLASTIC SYNDROME MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

11.1 Production Volume of Myelodysplastic Syndrome by Major Manufacturers

11.2 Production Value of Myelodysplastic Syndrome by Major Manufacturers

11.3 Basic Information of Myelodysplastic Syndrome by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Myelodysplastic Syndrome Major Manufacturer

11.3.2 Employees and Revenue Level of Myelodysplastic Syndrome Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

## **CHAPTER 12 MYELOYDYSPLASTIC SYNDROME MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

12.1 Celgene

12.1.1 Company profile

- 12.1.2 Representative Myelodysplastic Syndrome Product
- 12.1.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Celgene
- 12.2 Novartis
  - 12.2.1 Company profile
  - 12.2.2 Representative Myelodysplastic Syndrome Product
  - 12.2.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Novartis
- 12.3 Otsuka
  - 12.3.1 Company profile
  - 12.3.2 Representative Myelodysplastic Syndrome Product
  - 12.3.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Otsuka
- 12.4 Actinium Pharmaceuticals
  - 12.4.1 Company profile
  - 12.4.2 Representative Myelodysplastic Syndrome Product
  - 12.4.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Actinium Pharmaceuticals
- 12.5 Acceleron Pharma
  - 12.5.1 Company profile
  - 12.5.2 Representative Myelodysplastic Syndrome Product
  - 12.5.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Acceleron Pharma
- 12.6 Bellicum Pharmaceuticals
  - 12.6.1 Company profile
  - 12.6.2 Representative Myelodysplastic Syndrome Product
  - 12.6.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Bellicum Pharmaceuticals
- 12.7 Cornerstone Pharmaceuticals
  - 12.7.1 Company profile
  - 12.7.2 Representative Myelodysplastic Syndrome Product
  - 12.7.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Cornerstone Pharmaceuticals
- 12.8 CTI BioPharma
  - 12.8.1 Company profile
  - 12.8.2 Representative Myelodysplastic Syndrome Product
  - 12.8.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of CTI BioPharma
- 12.9 Onconova Therapeutics
  - 12.9.1 Company profile
  - 12.9.2 Representative Myelodysplastic Syndrome Product



12.9.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Onconova Therapeutics

12.10 Strategia Therapeutics

12.10.1 Company profile

12.10.2 Representative Myelodysplastic Syndrome Product

12.10.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Strategia Therapeutics

12.11 KaloBios Pharmaceuticals

12.11.1 Company profile

12.11.2 Representative Myelodysplastic Syndrome Product

12.11.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of KaloBios Pharmaceuticals

12.12 Kiadis Pharma

12.12.1 Company profile

12.12.2 Representative Myelodysplastic Syndrome Product

12.12.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Kiadis Pharma

12.13 Mirati Therapeutics

12.13.1 Company profile

12.13.2 Representative Myelodysplastic Syndrome Product

12.13.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Mirati Therapeutics

12.14 Astex

12.14.1 Company profile

12.14.2 Representative Myelodysplastic Syndrome Product

12.14.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Astex

12.15 Celator Pharmaceuticals

12.15.1 Company profile

12.15.2 Representative Myelodysplastic Syndrome Product

12.15.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Celator Pharmaceuticals

12.16 Eli-lilly

12.17 Sunesis Pharmaceuticals

12.18 Targazyme

12.19 Gamida Cell

12.20 GlaxoSmithKline

12.21 Sumitomo Dainippon Pharma

12.22 TetraLogic Pharmaceuticals

## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MYELODYSPLASTIC SYNDROME**

- 13.1 Industry Chain of Myelodysplastic Syndrome
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF MYELODYSPLASTIC SYNDROME**

- 14.1 Cost Structure Analysis of Myelodysplastic Syndrome
- 14.2 Raw Materials Cost Analysis of Myelodysplastic Syndrome
- 14.3 Labor Cost Analysis of Myelodysplastic Syndrome
- 14.4 Manufacturing Expenses Analysis of Myelodysplastic Syndrome

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

- 16.1 Methodology/Research Approach
  - 16.1.1 Research Programs/Design
  - 16.1.2 Market Size Estimation
  - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
  - 16.2.1 Secondary Sources
  - 16.2.2 Primary Sources
- 16.3 Reference

## I would like to order

Product name: Myelodysplastic Syndrome-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/M089E7D000AMEN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M089E7D000AMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970